<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00544115</url>
  </required_header>
  <id_info>
    <org_study_id>01089</org_study_id>
    <secondary_id>P30CA033572</secondary_id>
    <secondary_id>CHNMC-01089</secondary_id>
    <secondary_id>01089</secondary_id>
    <secondary_id>CDR0000566376</secondary_id>
    <nct_id>NCT00544115</nct_id>
  </id_info>
  <brief_title>Donor Peripheral Stem Cell Transplant in Treating Patients With Advanced Hematologic Cancer or Other Disorders</brief_title>
  <official_title>A Phase II Trial of Allogeneic Peripheral Blood Stem Cell Transplantation From Matched Unrelated Donors in Patients With Advanced Hematologic Malignancies and Hematological Disorders</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>City of Hope Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>City of Hope Medical Center</source>
  <brief_summary>
    <textblock>
      RATIONALE: Giving chemotherapy and total-body irradiation before a donor peripheral stem cell&#xD;
      transplant helps stop the growth of cancer or abnormal cells. It also helps stop the&#xD;
      patient's immune system from rejecting the donor's stem cells. When the healthy stem cells&#xD;
      from a donor are infused into the patient they may help the patient's bone marrow make stem&#xD;
      cells, red blood cells, white blood cells, and platelets. Sometimes the transplanted cells&#xD;
      from a donor can make an immune response against the body's normal cells. Giving tacrolimus,&#xD;
      methotrexate, cyclosporine, mycophenolate mofetil, and sirolimus before and after transplant&#xD;
      may stop this from happening.&#xD;
&#xD;
      PURPOSE: This phase II trial is studying how well donor peripheral stem cell transplant works&#xD;
      in treating patients with advanced hematologic cancer or other disorders.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  To evaluate hematopoietic recovery, using neutrophil and platelet engraftment as the&#xD;
           primary criterion, in patients with advanced hematologic malignancies or other disorders&#xD;
           undergoing allogeneic peripheral blood stem cell (PBSC) transplantation from matched&#xD;
           unrelated donors.&#xD;
&#xD;
        -  To evaluate the incidence of acute and chronic graft-versus-host-disease (GVHD) in&#xD;
           patients undergoing allogeneic PBSC transplantation from matched unrelated donors.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  To evaluate the impact of HLA class I and class II allele-matching on the incidence of&#xD;
           GVHD and on the survival outcome of these patients.&#xD;
&#xD;
        -  To evaluate overall survival, disease-free survival, and relapse in these patients.&#xD;
&#xD;
      OUTLINE: Patients are stratified according to type of conditioning regimen (myeloablative vs&#xD;
      reduced-intensity myeloablative). Patients are assigned to a conditioning regimen according&#xD;
      to diagnosis, age, disease status, prior radiotherapy, and prior autologous stem cell&#xD;
      transplantation.&#xD;
&#xD;
        -  Conditioning regimen:&#xD;
&#xD;
             -  Regimen I: Patients undergo total body irradiation (TBI) on days -7 to -4 and&#xD;
                receive cyclophosphamide IV on days -3 and -2. Alternatively, patients may receive&#xD;
                cyclophosphamide on days -7 and -6 and undergo TBI on days -4 to -1.&#xD;
&#xD;
             -  Regimen II: Patients receive busulfan IV over 2 hours once on day -8 and then every&#xD;
                6 hours on days -7 to -4. Patients also receive cyclophosphamide IV on days -3 and&#xD;
                -2.&#xD;
&#xD;
             -  Regimen III: Patients undergo TBI on days -7 to -4 and receive etoposide IV on day&#xD;
                -3.&#xD;
&#xD;
             -  Regimen IV: Patients receive fludarabine phosphate IV over 30 minutes on days -7 to&#xD;
                -3 and melphalan IV on day -2.&#xD;
&#xD;
             -  Regimen V: Patients receive fludarabine phosphate IV over 30 minutes on days -4 to&#xD;
                -2 and undergo TBI on day 0.&#xD;
&#xD;
             -  Regimen VI: Patients receive busulfan IV over 3 hours and fludarabine phosphate IV&#xD;
                over 30 minutes on days -5 to -2.&#xD;
&#xD;
        -  Allogeneic peripheral blood stem cell (PBSC) transplantation: All patients undergo&#xD;
           allogeneic PBSC transplantation on day 0.&#xD;
&#xD;
        -  Graft-versus-host disease (GVHD) prophylaxis: Patients receive one of the following GVHD&#xD;
           prophylaxis regimens:&#xD;
&#xD;
             -  Regimen A: Patients receive tacrolimus IV or orally on days -1 to 180 and&#xD;
                methotrexate IV on days 1, 3, 6, and 11.&#xD;
&#xD;
             -  Regimen B: Patients receive cyclosporine IV or orally twice daily on days -1 to&#xD;
                180, mycophenolate mofetil IV over 2 hours or orally twice daily on days 0-27, and&#xD;
                methotrexate IV on days 1, 3, and 6.&#xD;
&#xD;
             -  Regimen C: Patients receive tacrolimus IV continuously or orally, and oral&#xD;
                sirolimus beginning on day -3. Patients also receive methotrexate IV on days 1, 3,&#xD;
                and 6.&#xD;
&#xD;
      After completion of study therapy, patients are followed periodically.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">October 16, 2001</start_date>
  <completion_date type="Anticipated">December 15, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 15, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Neutrophil and platelet engraftment</measure>
    <time_frame>180 days post transplant</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of acute and chronic graft-versus-host disease (GVHD)</measure>
    <time_frame>1 year post transplant</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Impact of HLA class I and class II allele-matching on the incidence of GVHD and on the survival outcome</measure>
    <time_frame>1 year post transplant</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>2 years post transplant</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease-free survival</measure>
    <time_frame>2 years post transplant</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relapse</measure>
    <time_frame>At the time of relapse post transplant</time_frame>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Anticipated">260</enrollment>
  <condition>Chronic Myeloproliferative Disorders</condition>
  <condition>Graft Versus Host Disease</condition>
  <condition>Leukemia</condition>
  <condition>Lymphoma</condition>
  <condition>Multiple Myeloma and Plasma Cell Neoplasm</condition>
  <condition>Myelodysplastic Syndromes</condition>
  <condition>Myelodysplastic/Myeloproliferative Diseases</condition>
  <condition>Precancerous/Nonmalignant Condition</condition>
  <arm_group>
    <arm_group_label>Regimen I</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients undergo total body irradiation (TBI) on days -7 to -4 and receive cyclophosphamide IV on days -3 and -2. Alternatively, patients may receive cyclophosphamide on days -7 and -6 and undergo TBI on days -4 to -1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Regimen II</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients receive busulfan IV over 2 hours once on day -8 and then every 6 hours on days -7 to -4. Patients also receive cyclophosphamide IV on days -3 and -2.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Regimen III</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients undergo TBI on days -7 to -4 and receive etoposide IV on day -3.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Regimen IV</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients receive fludarabine phosphate IV over 30 minutes on days -7 to -3 and melphalan IV on day -2.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Regimen V</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients receive fludarabine phosphate IV over 30 minutes on days -4 to -2 and undergo TBI on day 0.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Regimen VI</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients receive busulfan IV over 3 hours and fludarabine phosphate IV over 30 minutes on days -5 to -2.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>busulfan</intervention_name>
    <arm_group_label>Regimen II</arm_group_label>
    <arm_group_label>Regimen VI</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cyclophosphamide</intervention_name>
    <arm_group_label>Regimen I</arm_group_label>
    <arm_group_label>Regimen II</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cyclosporine</intervention_name>
    <arm_group_label>Regimen I</arm_group_label>
    <arm_group_label>Regimen II</arm_group_label>
    <arm_group_label>Regimen III</arm_group_label>
    <arm_group_label>Regimen IV</arm_group_label>
    <arm_group_label>Regimen V</arm_group_label>
    <arm_group_label>Regimen VI</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>etoposide</intervention_name>
    <arm_group_label>Regimen III</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>fludarabine phosphate</intervention_name>
    <arm_group_label>Regimen IV</arm_group_label>
    <arm_group_label>Regimen V</arm_group_label>
    <arm_group_label>Regimen VI</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>melphalan</intervention_name>
    <arm_group_label>Regimen IV</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>methotrexate</intervention_name>
    <arm_group_label>Regimen I</arm_group_label>
    <arm_group_label>Regimen II</arm_group_label>
    <arm_group_label>Regimen III</arm_group_label>
    <arm_group_label>Regimen IV</arm_group_label>
    <arm_group_label>Regimen V</arm_group_label>
    <arm_group_label>Regimen VI</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>mycophenolate mofetil</intervention_name>
    <arm_group_label>Regimen I</arm_group_label>
    <arm_group_label>Regimen II</arm_group_label>
    <arm_group_label>Regimen III</arm_group_label>
    <arm_group_label>Regimen IV</arm_group_label>
    <arm_group_label>Regimen V</arm_group_label>
    <arm_group_label>Regimen VI</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>sirolimus</intervention_name>
    <arm_group_label>Regimen I</arm_group_label>
    <arm_group_label>Regimen II</arm_group_label>
    <arm_group_label>Regimen III</arm_group_label>
    <arm_group_label>Regimen IV</arm_group_label>
    <arm_group_label>Regimen V</arm_group_label>
    <arm_group_label>Regimen VI</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>tacrolimus</intervention_name>
    <arm_group_label>Regimen I</arm_group_label>
    <arm_group_label>Regimen II</arm_group_label>
    <arm_group_label>Regimen III</arm_group_label>
    <arm_group_label>Regimen IV</arm_group_label>
    <arm_group_label>Regimen V</arm_group_label>
    <arm_group_label>Regimen VI</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>allogeneic hematopoietic stem cell transplantation</intervention_name>
    <arm_group_label>Regimen I</arm_group_label>
    <arm_group_label>Regimen II</arm_group_label>
    <arm_group_label>Regimen III</arm_group_label>
    <arm_group_label>Regimen IV</arm_group_label>
    <arm_group_label>Regimen V</arm_group_label>
    <arm_group_label>Regimen VI</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>peripheral blood stem cell transplantation</intervention_name>
    <arm_group_label>Regimen I</arm_group_label>
    <arm_group_label>Regimen II</arm_group_label>
    <arm_group_label>Regimen III</arm_group_label>
    <arm_group_label>Regimen IV</arm_group_label>
    <arm_group_label>Regimen V</arm_group_label>
    <arm_group_label>Regimen VI</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>total-body irradiation</intervention_name>
    <arm_group_label>Regimen I</arm_group_label>
    <arm_group_label>Regimen III</arm_group_label>
    <arm_group_label>Regimen V</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Diagnosis of one of the following:&#xD;
&#xD;
               -  Acute lymphocytic leukemia (ALL), meeting one of the following criteria:&#xD;
&#xD;
                    -  In first relapse or beyond&#xD;
&#xD;
                    -  High-risk ALL, defined by any of the following:&#xD;
&#xD;
                         -  Hypoploidy (≤ 44 chromosomes)&#xD;
&#xD;
                         -  Pseudodiploidy with translocations or molecular evidence of t(9;22),&#xD;
                            11q23, or t(8;14), excluding B-cell ALL&#xD;
&#xD;
                         -  Elevated WBC at presentation (WBC &gt; 20,000/mm³ [for patients &gt; 18 years&#xD;
                            of age]; WBC &gt; 200,000/mm³ [for patients 12-18 years of age])&#xD;
&#xD;
               -  Acute myeloid leukemia (AML), meeting one of the following criteria:&#xD;
&#xD;
                    -  In first complete remission&#xD;
&#xD;
                    -  Failed to achieve remission&#xD;
&#xD;
                    -  In first relapse or beyond&#xD;
&#xD;
                    -  Secondary AML (&gt; 30% blasts in marrow aspirate)&#xD;
&#xD;
                         -  Should receive induction chemotherapy to obtain remission, if possible,&#xD;
                            before transplant&#xD;
&#xD;
               -  Chronic myelogenous leukemia, meeting one of the following criteria:&#xD;
&#xD;
                    -  In first or second chronic phase or accelerated phase&#xD;
&#xD;
                    -  In blast crisis, defined as &gt; 30% promyelocytes plus blasts in the bone&#xD;
                       marrow&#xD;
&#xD;
               -  Myelodysplastic syndromes, including any of the following:&#xD;
&#xD;
                    -  Refractory anemia with excess blasts (RAEB)&#xD;
&#xD;
                    -  Chronic myelomonocytic leukemia&#xD;
&#xD;
                    -  RAEB in transformation&#xD;
&#xD;
               -  Refractory non-Hodgkin lymphoma, chronic lymphocytic leukemia, Hodgkin lymphoma,&#xD;
                  or multiple myeloma&#xD;
&#xD;
                    -  Received and failed front-line therapy, high-dose therapy and autologous&#xD;
                       stem cell transplantation, or salvage therapy&#xD;
&#xD;
               -  Myeloproliferative disorders/myelofibrosis may be allowed on a case by case basis&#xD;
&#xD;
               -  Severe aplastic anemia, paroxysmal nocturnal hemoglobinuria, or any other&#xD;
                  hematologic disorder requiring transplantation&#xD;
&#xD;
          -  Patients &gt; 55 years of age with hematologic diseases treatable by allogeneic stem cell&#xD;
             transplantation who are not eligible for IRB 99190 are eligible&#xD;
&#xD;
          -  No uncontrolled CNS involvement of disease&#xD;
&#xD;
          -  No matched (6/6) related donor available&#xD;
&#xD;
          -  HLA-identical unrelated donor available&#xD;
&#xD;
               -  HLA-phenotypically identical for HLA-A and HLA-B alleles and identical for DRB1&#xD;
                  alleles by DNA typing for both class I and class II antigens&#xD;
&#xD;
                    -  Allele mismatch for HLA class I (i.e., B 2701 vs B 2702) allowed if no&#xD;
                       alternative donors&#xD;
&#xD;
                    -  Allele mismatch for class II (i.e., DRB1 0401 vs 0402) or minor mismatch for&#xD;
                       class I cross reactive group (CREG) (i.e., A 2 vs A 28) allowed in patients&#xD;
                       ≤ 35 years of age requiring urgent transplant&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
          -  Karnofsky performance status 50-100%&#xD;
&#xD;
          -  Life expectancy &gt; 8 weeks&#xD;
&#xD;
          -  LVEF ≥ 45% at rest&#xD;
&#xD;
          -  AST ≤ 2 times normal (unless liver function abnormality is due to underlying disease)&#xD;
&#xD;
          -  Total bilirubin &lt; 1.5 times normal (unless liver function abnormality is due to&#xD;
             underlying disease)&#xD;
&#xD;
          -  Creatinine ≤ 1.5 times normal OR creatinine clearance ≥ 60 mL/min&#xD;
&#xD;
          -  DLCO ≥ 40% of predicted (corrected for hemoglobin)&#xD;
&#xD;
          -  No coexisting medical problem that would significantly increase the risk of the&#xD;
             transplant procedure&#xD;
&#xD;
          -  HIV negative&#xD;
&#xD;
          -  Not pregnant&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>120 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Auayporn P. Nademanee, MD</last_name>
    <role>Study Chair</role>
    <affiliation>City of Hope Comprehensive Cancer Center</affiliation>
  </overall_official>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>October 13, 2007</study_first_submitted>
  <study_first_submitted_qc>October 13, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 16, 2007</study_first_posted>
  <last_update_submitted>June 10, 2021</last_update_submitted>
  <last_update_submitted_qc>June 10, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 14, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>graft versus host disease</keyword>
  <keyword>recurrent adult acute lymphoblastic leukemia</keyword>
  <keyword>recurrent childhood acute lymphoblastic leukemia</keyword>
  <keyword>untreated adult acute lymphoblastic leukemia</keyword>
  <keyword>untreated childhood acute lymphoblastic leukemia</keyword>
  <keyword>de novo myelodysplastic syndromes</keyword>
  <keyword>previously treated myelodysplastic syndromes</keyword>
  <keyword>secondary myelodysplastic syndromes</keyword>
  <keyword>refractory anemia with excess blasts in transformation</keyword>
  <keyword>refractory anemia with excess blasts</keyword>
  <keyword>atypical chronic myeloid leukemia</keyword>
  <keyword>chronic myelomonocytic leukemia</keyword>
  <keyword>juvenile myelomonocytic leukemia</keyword>
  <keyword>myelodysplastic/myeloproliferative disease, unclassifiable</keyword>
  <keyword>recurrent adult acute myeloid leukemia</keyword>
  <keyword>recurrent childhood acute myeloid leukemia</keyword>
  <keyword>adult acute myeloid leukemia in remission</keyword>
  <keyword>childhood acute myeloid leukemia in remission</keyword>
  <keyword>secondary acute myeloid leukemia</keyword>
  <keyword>adult acute myeloid leukemia with 11q23 (MLL) abnormalities</keyword>
  <keyword>adult acute myeloid leukemia with inv(16)(p13;q22)</keyword>
  <keyword>adult acute myeloid leukemia with t(15;17)(q22;q12)</keyword>
  <keyword>adult acute myeloid leukemia with t(16;16)(p13;q22)</keyword>
  <keyword>adult acute myeloid leukemia with t(8;21)(q22;q22)</keyword>
  <keyword>accelerated phase chronic myelogenous leukemia</keyword>
  <keyword>blastic phase chronic myelogenous leukemia</keyword>
  <keyword>childhood chronic myelogenous leukemia</keyword>
  <keyword>chronic phase chronic myelogenous leukemia</keyword>
  <keyword>relapsing chronic myelogenous leukemia</keyword>
  <keyword>chronic eosinophilic leukemia</keyword>
  <keyword>chronic idiopathic myelofibrosis</keyword>
  <keyword>chronic neutrophilic leukemia</keyword>
  <keyword>essential thrombocythemia</keyword>
  <keyword>polycythemia vera</keyword>
  <keyword>Waldenstrom macroglobulinemia</keyword>
  <keyword>extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue</keyword>
  <keyword>nodal marginal zone B-cell lymphoma</keyword>
  <keyword>recurrent adult Burkitt lymphoma</keyword>
  <keyword>recurrent adult diffuse large cell lymphoma</keyword>
  <keyword>recurrent adult diffuse mixed cell lymphoma</keyword>
  <keyword>recurrent adult diffuse small cleaved cell lymphoma</keyword>
  <keyword>recurrent adult immunoblastic large cell lymphoma</keyword>
  <keyword>recurrent adult lymphoblastic lymphoma</keyword>
  <keyword>recurrent grade 1 follicular lymphoma</keyword>
  <keyword>recurrent grade 2 follicular lymphoma</keyword>
  <keyword>recurrent grade 3 follicular lymphoma</keyword>
  <keyword>recurrent mantle cell lymphoma</keyword>
  <keyword>recurrent marginal zone lymphoma</keyword>
  <keyword>recurrent small lymphocytic lymphoma</keyword>
  <keyword>splenic marginal zone lymphoma</keyword>
  <keyword>recurrent childhood grade III lymphomatoid granulomatosis</keyword>
  <keyword>childhood nasal type extranodal NK/T-cell lymphoma</keyword>
  <keyword>recurrent childhood large cell lymphoma</keyword>
  <keyword>childhood diffuse large cell lymphoma</keyword>
  <keyword>childhood immunoblastic large cell lymphoma</keyword>
  <keyword>recurrent childhood lymphoblastic lymphoma</keyword>
  <keyword>Burkitt lymphoma</keyword>
  <keyword>recurrent childhood small noncleaved cell lymphoma</keyword>
  <keyword>anaplastic large cell lymphoma</keyword>
  <keyword>angioimmunoblastic T-cell lymphoma</keyword>
  <keyword>recurrent adult T-cell leukemia/lymphoma</keyword>
  <keyword>recurrent adult grade III lymphomatoid granulomatosis</keyword>
  <keyword>adult nasal type extranodal NK/T-cell lymphoma</keyword>
  <keyword>recurrent adult Hodgkin lymphoma</keyword>
  <keyword>recurrent/refractory childhood Hodgkin lymphoma</keyword>
  <keyword>refractory chronic lymphocytic leukemia</keyword>
  <keyword>refractory multiple myeloma</keyword>
  <keyword>stage III multiple myeloma</keyword>
  <keyword>aplastic anemia</keyword>
  <keyword>paroxysmal nocturnal hemoglobinuria</keyword>
  <keyword>adult acute lymphoblastic leukemia in remission</keyword>
  <keyword>childhood acute lymphoblastic leukemia in remission</keyword>
  <keyword>recurrent cutaneous T-cell non-Hodgkin lymphoma</keyword>
  <keyword>recurrent mycosis fungoides/Sezary syndrome</keyword>
  <keyword>stage II multiple myeloma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
    <mesh_term>Preleukemia</mesh_term>
    <mesh_term>Plasmacytoma</mesh_term>
    <mesh_term>Precancerous Conditions</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
    <mesh_term>Myeloproliferative Disorders</mesh_term>
    <mesh_term>Myelodysplastic-Myeloproliferative Diseases</mesh_term>
    <mesh_term>Graft vs Host Disease</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclosporine</mesh_term>
    <mesh_term>Sirolimus</mesh_term>
    <mesh_term>Mycophenolic Acid</mesh_term>
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Melphalan</mesh_term>
    <mesh_term>Busulfan</mesh_term>
    <mesh_term>Methotrexate</mesh_term>
    <mesh_term>Fludarabine</mesh_term>
    <mesh_term>Fludarabine phosphate</mesh_term>
    <mesh_term>Etoposide</mesh_term>
    <mesh_term>Tacrolimus</mesh_term>
    <mesh_term>Cyclosporins</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

